Every 8-K that Erasca, Inc. (ERAS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ERAS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERAS filings page.
Erasca, Inc. (ERAS) reports that the U.S. Food and Drug Administration has granted Fast Track Designation (FTD) to its product candidate ERAS-0015 for treating patients with metastatic pancreatic adenocarcinoma. FTD is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical needs through more frequent FDA interactions and potential access to accelerated approval, priority review, and rolling review if relevant criteria are met.
Erasca notes that FTD does not change approval standards and may not shorten review time or increase the likelihood of marketing approval. The company highlights plans involving ERAS-0015, including a potential phase 3 trial in pancreatic cancer and two potentially registration-enabling trials in lung cancer, while emphasizing significant clinical, regulatory, and safety risks and uncertainties.
Erasca, Inc. reported second quarter 2026 results and business updates centered on its RAS/MAPK-targeted oncology pipeline. Lead candidate ERAS-0015 showed a 57% uORR8wk as monotherapy in second-line or later KRAS G12X pancreatic cancer at the 32 mg once-daily dose, with ongoing treatment for all responders and favorable tolerability, including no dose-limiting toxicities or treatment-related discontinuations. The company is advancing ERAS-0015 toward three potentially registration-enabling trials in pancreatic and lung cancers, with multiple Phase 1 monotherapy and combination data readouts expected in the first half of 2027. ERAS-4001, a potential first-in-class pan-KRAS inhibitor, has preliminary Phase 1 monotherapy data expected in the second half of 2026.
Cash, cash equivalents, and marketable securities were $384.3 million as of June 30, 2026, up from $341.8 million at year-end 2025, and were further bolstered by an upsized July 2026 public offering raising approximately $632.5 million in gross proceeds. The company expects its capital, including proceeds from the July offering, to be sufficient to fund its stated key upcoming milestones. For the quarter, research and development expenses were $35.9 million, general and administrative expenses were $11.7 million, and net loss was $44.1 million, or $(0.14) per share, compared with a net loss of $33.9 million, or $(0.12) per share, in the prior-year quarter.
Erasca, Inc. appointed Charles S. Fuchs, M.D., M.P.H., age 66, as President, Research & Development effective August 10, 2026. He has more than three decades of oncology leadership across academia and biopharmaceutical companies, including senior roles at Genentech, Roche, Tubulis, Yale Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute. There are no related-party relationships or appointment arrangements disclosed.
Under an employment offer letter, Dr. Fuchs will receive an annual base salary of $570,000, a target bonus equal to 45% of base salary, and stock options to purchase 1,300,000 shares of common stock, vesting over four years. Of these, 1,278,520 options were granted under a newly adopted 2026 Employment Inducement Incentive Award Plan, with 6,200,000 shares reserved for awards. The options will have an exercise price equal to the closing price on the grant date. Dr. Fuchs is designated a Tier 1 Covered Employee under the company’s severance plan and has entered into the company’s standard indemnification agreement.
Erasca, Inc. entered into an underwriting agreement for a primary underwritten public offering of 31,428,572 shares of common stock at $17.50 per share. Underwriters will purchase the shares at $16.45 per share and have a 30-day option to buy up to 4,714,285 additional shares at the public price, less discounts.
The offering, made off an automatically effective Form S-3 shelf, is expected to generate net proceeds of approximately $516.0 million, or $593.5 million if the option is fully exercised, and to close on July 15, 2026 subject to customary conditions. Erasca plans to use the proceeds, together with existing cash, to fund research and development of its oncology product candidates, other development programs, and for working capital and general corporate purposes.
Erasca, Inc. reported updated preliminary Phase 1 data from the ongoing AURORAS-1 trial of ERAS-0015, described as a potentially best-in-class, pan-RAS molecular glue in patients with RAS-mutant solid tumors. The update adds patients and longer follow-up to earlier April 2026 results.
Among 72 patients with RAS-mutant NSCLC and pancreatic ductal adenocarcinoma treated at the protocol-amended dose, treatment-related adverse events were mainly low grade. Rash occurred in 52 patients (72%), diarrhea in 23 (32%), stomatitis in 14 (19%), and nausea in 10 (14%). Events led to dose interruptions in 9 patients (13%) and dose reductions in 6 (8%), with no treatment-related adverse events causing discontinuation.
The company highlights encouraging monotherapy responses in second-line or later KRAS G12X pancreatic ductal adenocarcinoma, promising combination potential with panitumumab in metastatic colorectal cancer, and plans to accelerate potentially registration-enabling studies. Extensive risk disclosures emphasize that these are interim, forward-looking assessments subject to delay, changing data, regulatory feedback, safety and efficacy outcomes, intellectual property disputes, and funding constraints.
Erasca, Inc. held its annual meeting of stockholders on June 26, 2026. As of the April 27, 2026 record date, 310,965,971 shares were entitled to vote, and 266,073,906 shares were represented in person or by proxy, establishing a strong quorum.
Stockholders elected three Class II directors—Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.—to three-year terms expiring at the 2029 annual meeting. Votes for these nominees ranged from 219,569,944 to 223,863,013, with 25,593,152 to 29,886,221 withheld and 16,617,741 broker non-votes.
Stockholders also ratified the appointment of KPMG LLP as Erasca’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with no broker non-votes recorded for this proposal.
Erasca reported first quarter 2026 results highlighting major investment in its RAS-targeting pipeline. The company ended March 31, 2026 with $408.5 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2028.
Total operating expenses rose to $187.9 million, driven by $150.0 million of in-process R&D expense to obtain worldwide rights to ERAS-0015, alongside $27.3 million in R&D and $10.6 million in G&A. Net loss widened to $183.4 million, or $(0.60) per share.
Strategically, Erasca advanced ERAS-0015 and ERAS-4001, signed clinical trial collaborations with Merck and Tango Therapeutics, secured a U.S. composition of matter patent for ERAS-4001 through June 2043, expanded ERAS-0015 licensing territory, and completed an upsized public offering raising approximately $258.8 million in gross proceeds.
Erasca, Inc. reported positive preliminary Phase 1 dose escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. Early results come from the AURORAS-1 trial in the United States and the JYP0015M101 trial in China.
The studies enroll patients with colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma, tumor types where KRAS mutations affect an estimated 74,000, 55,000 and 50,000 patients per year in the United States. Erasca has already started ERAS-0015 monotherapy expansion and combination dose escalation cohorts in the United States earlier than its prior guidance.
The company emphasizes that the data are preliminary, include information from a third-party licensor and involve cross-study comparisons that are inherently limited. It highlights multiple development and regulatory risks, including the possibility that future, more complete trial results may differ from current observations.
Erasca, Inc. updated the expected timing for initial Phase 1 monotherapy data from its pan-RAS molecular glue ERAS-0015, now guiding that data from the AURORAS-1 and JYP0015M101 trials will be available no later than mid-May 2026, compared with its prior expectation of the first half of 2026.
AURORAS-1 is evaluating ERAS-0015 in patients with RAS-mutant solid tumors, while licensor Guangzhou Joyo Pharmatech Co., Ltd. is running JYP0015M101 in China in patients with advanced solid tumors harboring specific RAS mutations. The company also highlights typical forward-looking statement risks and directs readers to its risk factor disclosures.
Erasca, Inc. reported fourth quarter and full year 2025 results alongside business and pipeline updates. For 2025, net loss narrowed to $124.5 million, or $(0.44) per share, from $161.7 million, or $(0.69) per share, in 2024 as operating expenses declined.
Research and development expenses fell to $92.9 million from $115.4 million, while general and administrative expenses decreased to $38.6 million from $41.7 million. Cash, cash equivalents, and marketable securities were $341.8 million as of December 31, 2025, down from $440.5 million a year earlier.
The company completed an upsized public offering in January 2026, raising approximately $258.8 million in gross proceeds and expects pro forma cash of $434 million to fund operations into the second half of 2028. Erasca highlighted encouraging early clinical activity for ERAS-0015, continued advancement of ERAS-4001, and new U.S. composition-of-matter patents supporting its RAS-targeting franchise, with multiple Phase 1 data readouts and trial expansions planned in 2026 and 2027.
Erasca, Inc. reported preliminary cash, cash equivalents and marketable securities of approximately $341.8 million as of December 31, 2025. The company also closed an upsized public offering of 25,875,000 common shares, including underwriters’ full overallotment exercise.
Erasca estimates net proceeds of $242.7 million from this January 2026 offering after underwriting discounts and expenses. Based on this cash position and the offering proceeds, the company estimates it has sufficient cash resources to fund operations into the first half of 2029. These figures are preliminary, unaudited and subject to completion of year-end financial procedures.
Erasca, Inc. entered into an underwriting agreement to sell 22,500,000 shares of its common stock at a public offering price of $10.00 per share, with underwriters purchasing at $9.40 per share. The company also granted the underwriters a 30-day option to buy up to 3,375,000 additional shares at the same public price, less discounts and commissions. Net proceeds to Erasca are expected to be about $211.0 million, or approximately $242.7 million if the option is fully exercised, after fees and expenses. The offering is expected to close on January 23, 2026, subject to customary closing conditions, and is being conducted under an effective shelf registration statement and related prospectus supplement.
Erasca, Inc. reported preliminary year-end liquidity, stating that as of December 31, 2025, its cash, cash equivalents and marketable securities totaled approximately $341.8 million. This figure is based on unaudited internal information and management estimates and is part of the company’s results of operations and financial condition disclosure.
The company emphasized that this amount may change once it completes its year-end financial closing procedures and reviews of internal controls, and after its independent registered public accounting firm conducts its audit. The disclosure is deemed filed under the securities laws and is subject to the usual forward-looking statement cautions and risk factors referenced from prior SEC filings.
Erasca, Inc. filed a report highlighting new clinical progress and upcoming milestones for its RAS-targeting drug pipeline and updating its investor presentation. The company reported that ERAS-0015, described as a potential best-in-class RAS-targeting molecule in the AURORAS-1 Phase 1 trial, is advancing dose escalation faster than anticipated, with ongoing confirmed and unconfirmed partial responses at doses starting from 8 mg once daily and a favorable safety profile with no dose-limiting toxicities at doses evaluated through a January 7, 2026 cutoff. Initial Phase 1 monotherapy data for ERAS-0015 in RAS-mutant solid tumors are planned in the first half of 2026, with expansion and combination cohorts through 2027. ERAS-4001, described as a potential first-in-class pan-KRAS inhibitor in the BOREALIS-1 Phase 1 trial, continues dose escalation and has planned monotherapy data in the second half of 2026 and further expansion work in 2027. Erasca also updated its corporate presentation, which will be used at the J.P. Morgan Healthcare Conference and posted on its website.
Erasca, Inc. filed a current report to note that it has announced its financial results for the three months ended September 30, 2025. The company released these quarterly results through a press release dated November 12, 2025, which is included as Exhibit 99.1. The report specifies that this earnings information is being furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced.
Erasca, Inc. announced its financial results for the three months ended June 30, 2025 and furnished a press release containing the full results as Exhibit 99.1 to this Current Report. The filing notes the press release is being furnished rather than "filed," so it is not subject to Section 18 liability and is not incorporated by reference into other Securities Act or Exchange Act filings except by specific reference.
The Current Report identifies Exhibit 99.1 (press release) and a Cover Page Interactive Data File (104) as exhibits. No numerical financial data or consolidated financial statements are included in the text of this Form 8-K; readers are referred to the attached Exhibit 99.1 for the detailed results.
Erasca (Nasdaq: ERAS) filed a Form 8-K disclosing the 24 June 2025 annual meeting results. 241.8 million of 283.3 million entitled shares were represented (≈85%).
- Director elections: Jonathan Lim 196.99 M for / 2.19 M withheld; James Bristol 178.36 M for / 20.81 M withheld; Valerie Harding-Start 177.00 M for / 22.17 M withheld. All three Class I directors were elected for terms expiring in 2028.
- Auditor ratification: KPMG LLP received 240.25 M for, 1.27 M withheld, 0.31 M against; 0 broker non-votes.
No additional proposals were presented, and the filing notes no changes to governance, strategy, or capital structure.